247 related articles for article (PubMed ID: 29339806)
21. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
Knipper S; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2020 Mar; 38(3):79.e9-79.e14. PubMed ID: 31653563
[TBL] [Abstract][Full Text] [Related]
22. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
[TBL] [Abstract][Full Text] [Related]
23. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Graefen M; Gallucci M; Shariat SF; Mantica G; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
J Urol; 2022 Feb; 207(2):375-384. PubMed ID: 34555930
[TBL] [Abstract][Full Text] [Related]
24. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
25. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
26. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
28. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
30. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
[TBL] [Abstract][Full Text] [Related]
32. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
34. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
35. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
36. Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis.
Mazzone E; Mistretta FA; Knipper S; Palumbo C; Tian Z; Pecoraro A; Preisser F; Gallina A; Shariat SF; Saad F; Graefen M; Montorsi F; Briganti A; Karakiewicz PI
BJU Int; 2019 Dec; 124(6):1006-1013. PubMed ID: 31144770
[TBL] [Abstract][Full Text] [Related]
37. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
38. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
39. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Kitsukawa S; Masuda H; Ishikawa Y; Kozuka T; Oguchi M; Kohno A; Fukui I
Int J Clin Oncol; 2014 Dec; 19(6):1085-91. PubMed ID: 24346487
[TBL] [Abstract][Full Text] [Related]
40. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]